NicoDerm CQ Patch — Competitive Intelligence Brief

NicoDerm CQ Patch (NicoDerm CQ Patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy (NRT). Area: Addiction Medicine / Smoking Cessation.

marketed Nicotine replacement therapy (NRT) Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

NicoDerm CQ Patch (NicoDerm CQ Patch) — Chrono Therapeutics, Inc.. NicoDerm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NicoDerm CQ Patch TARGET	NicoDerm CQ Patch	Chrono Therapeutics, Inc.	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
bupropion + nicotine gum	bupropion + nicotine gum	University of Wisconsin, Madison	marketed	Combination smoking cessation therapy (antidepressant + nicotine replacement)	Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)
NRT (NicoDerm CQ)	NRT (NicoDerm CQ)	University of California, San Francisco	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Naltrexone Tablet and Nicotine Patch	Naltrexone Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Opioid antagonist + nicotine replacement therapy combination	Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine)
Nicotine Patch + Nicotine Gum	Nicotine Patch + Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy (NRT) class)

1. University of Wisconsin, Madison · 4 drugs in this class
2. Ottawa Heart Institute Research Corporation · 1 drug in this class
3. The Scripps Research Institute · 1 drug in this class
4. US Department of Veterans Affairs · 1 drug in this class
5. Chrono Therapeutics, Inc. · 1 drug in this class
6. University of Chicago · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Miami · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class